# SANUWAVE Health, Inc.: overview SNWV · Nasdaq · CIK 1417663 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/snwv.md) · [Financials](/companies/snwv/financials.md) · [Filings](/companies/snwv/filings.md) · [Insiders](/companies/snwv/insiders.md) Latest reported revenue: [$9.7m](/filings/0001628280-26-054393.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-054393). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.3](/filings/0001628280-25-050280.md) | [10.3 d](/filings/0001628280-25-014141.md) | [9.3](/filings/0001628280-25-023881.md) | [10.1](/filings/0001628280-25-038937.md) | [11.4](/filings/0001628280-25-050280.md) | [13.2 d](/filings/0001628280-26-021443.md) | [9.6](/filings/0001628280-26-034145.md) | [9.7](/filings/0001628280-26-054393.md) | | Gross margin | % | [76.1%](/filings/0001628280-25-050280.md) | [78.2% d](/filings/0001628280-26-021443.md) | [79.4%](/filings/0001628280-26-034145.md) | [77.3%](/filings/0001628280-26-054393.md) | [76.6%](/filings/0001628280-26-021443.md) | [75.8% d](/filings/0001628280-26-021443.md) | [77.3%](/filings/0001628280-26-034145.md) | [76.2%](/filings/0001628280-26-054393.md) | | Operating margin | % | [16.0%](/filings/0001628280-26-021443.md) | [19.6% d](/filings/0001628280-26-021443.md) | [6.5%](/filings/0001628280-26-034145.md) | [14.2%](/filings/0001628280-26-054393.md) | [7.9%](/filings/0001628280-26-021443.md) | [15.2% d](/filings/0001628280-26-021443.md) | [(11.7%)](/filings/0001628280-26-034145.md) | [(2.9%)](/filings/0001628280-26-054393.md) | | Net margin | % | [(227.8%)](/filings/0001628280-26-021443.md) | [(129.5%) d](/filings/0001628280-26-021443.md) | [(65.8%)](/filings/0001628280-26-034145.md) | [5.4%](/filings/0001628280-26-054393.md) | [84.8%](/filings/0001628280-26-021443.md) | [58.3% d](/filings/0001628280-26-021443.md) | [(15.0%)](/filings/0001628280-26-034145.md) | [(7.0%)](/filings/0001628280-26-054393.md) | | Diluted EPS | $ per share | [(6.65)](/filings/0001628280-26-021443.md) | not reported | [(0.72)](/filings/0001628280-26-034145.md) | [(0.04)](/filings/0001628280-26-054393.md) | [0.39](/filings/0001628280-26-021443.md) | not reported | [(0.17)](/filings/0001628280-26-034145.md) | [(0.08)](/filings/0001628280-26-054393.md) | | Free cash flow | $m | [1.2 d](/filings/0001628280-26-021443.md) | [0.5 d](/filings/0001628280-26-021443.md) | [(1.7)](/filings/0001628280-26-034145.md) | [(0.2) d](/filings/0001628280-26-054393.md) | [0.6 d](/filings/0001628280-26-021443.md) | [3.2 d](/filings/0001628280-26-021443.md) | [0.4](/filings/0001628280-26-034145.md) | [0.1 d](/filings/0001628280-26-054393.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.4](/filings/0001140361-23-015331.md) | [15.5](/filings/0001140361-24-014611.md) | [19.3](/filings/0001628280-25-014141.md) | [32.3](/filings/0001628280-25-014141.md) | [44.1](/filings/0001628280-26-021443.md) | | Gross margin | % | [70.5%](/filings/0001140361-23-015331.md) | [80.0%](/filings/0001140361-24-014611.md) | [74.6%](/filings/0001628280-25-014141.md) | [75.9%](/filings/0001628280-26-021443.md) | [77.1%](/filings/0001628280-26-021443.md) | | Operating margin | % | [(124.2%)](/filings/0001140361-23-015331.md) | [(57.7%)](/filings/0001140361-24-014611.md) | [(2.8%)](/filings/0001628280-25-014141.md) | [11.9%](/filings/0001628280-26-021443.md) | [11.2%](/filings/0001628280-26-021443.md) | | Net margin | % | [(239.5%)](/filings/0001140361-23-015331.md) | [(66.4%)](/filings/0001140361-24-014611.md) | [(134.0%)](/filings/0001628280-25-014141.md) | [(102.3%)](/filings/0001628280-26-021443.md) | [26.8%](/filings/0001628280-26-021443.md) | | Diluted EPS | $ per share | [(0.05)](/filings/0001140361-23-015331.md) | [(0.02)](/filings/0001140361-24-014611.md) | [(12.19)](/filings/0001628280-25-014141.md) | [(7.41)](/filings/0001628280-26-021443.md) | [0.41](/filings/0001628280-26-021443.md) | | Free cash flow | $m | [(6.9)](/filings/0001140361-23-015331.md) | not reported | [(4.5)](/filings/0001628280-25-014141.md) | [2.0](/filings/0001628280-26-021443.md) | [1.9](/filings/0001628280-26-021443.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/snwv/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Solas Capital Management, LLC](/funds/1604867.md) | 2026-06-30 | $6.1m | 610,968 | | Added +323,454 | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $4.5m | 454,550 | | Unchanged | | [Praetorian PR LLC](/funds/1949877.md) | 2026-06-30 | $4.0m | 395,000 | | Added +45,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.5m | 352,756 | | Added +3,882 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $3.1m | 306,140 | | Reduced −675,127 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.6m | 256,791 | | Added +46,528 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.6m | 159,867 | | Reduced −321,673 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $861.4k | 86,098 | | Reduced −85,700 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $594.7k | 59,473 | | Added +41,375 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $431.0k | 43,097 | | Reduced −6,184 | ## Recent filings [All 741 filings](/companies/snwv/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 17:15 ET | [8-K](/filings/0001628280-26-067943.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-26-067943 | | 2026-09-25 | 16:38 ET | [8-K](/filings/0001628280-26-063594.md) | 3.01 Delisting notice | 0001628280-26-063594 | | 2026-08-06 | 17:07 ET | [8-K](/filings/0001628280-26-054459.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-054459 | | 2026-08-06 | 16:37 ET | [10-Q](/filings/0001628280-26-054393.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054393 | | 2026-07-13 | 16:38 ET | [8-K](/filings/0001628280-26-048043.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-048043 | | 2026-06-16 | 08:07 ET | [8-K](/filings/0001628280-26-043419.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-043419 | | 2026-06-15 | 17:27 ET | [8-K](/filings/0001628280-26-043306.md) | 5.07 Shareholder vote results | 0001628280-26-043306 | | 2026-05-12 | 16:33 ET | [8-K](/filings/0001628280-26-034149.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-034149 | | 2026-05-12 | 16:32 ET | [10-Q](/filings/0001628280-26-034145.md) | Quarterly report, period 2026-03-31 | 0001628280-26-034145 | | 2026-04-29 | 16:05 ET | [DEF 14A](/filings/0001140361-26-017806.md) | Proxy statement, period 2026-06-11 | 0001140361-26-017806 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-021443.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7e9d5499-10b5-4415-88e8-7c91f9d2d5f7) ## About the filer - CIK: 1417663 - Tickers: SNWV - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:34 ET. No prices; not investment advice.